BeOne Medicines Unveils Promising Clinical Data on Novel BCL2 and BTK Therapies at ASH 2025

Reuters11-20

BeOne Medicines Unveils Promising Clinical Data on Novel BCL2 and BTK Therapies at ASH 2025

BeOne Medicines AG has announced the presentation of new clinical data from its hematology portfolio at the upcoming 67th American Society of Hematology $(ASH)$ Annual Meeting and Exposition, scheduled for December 6-9, 2025, in Orlando, Florida. Nearly 50 abstracts have been accepted, including six oral presentations. Key highlights include results from the Phase 1/1b study of the BCL2 inhibitor sonrotoclax in combination with obinutuzumab for treatment-naïve CLL/SLL, as well as initial data on a triplet regimen of sonrotoclax, BRUKINSA (zanubrutinib), and obinutuzumab. Preliminary findings from a Phase 1/1b study of BGB-21447, a next-generation BCL2 inhibitor in patients with B-cell non-Hodgkin lymphoma, will also be shared. These results will be presented at the ASH 2025 meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeOne Medicines AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20251120303213) on November 20, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584380781?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-20 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584380781","market":"us","top_or_hot":-1,"title":"BeOne Medicines Unveils Promising Clinical Data on Novel BCL2 and BTK Therapies at ASH 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BeOne Medicines Unveils Promising Clinical Data on Novel BCL2 and BTK Therapies at ASH 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BeOne Medicines AG has announced the presentation of new clinical data from its hematology portfolio at the upcoming 67th American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> Annual Meeting and Exposition, scheduled for December 6-9, 2025, in Orlando, Florida. Nearly 50 abstracts have been accepted, including six oral presentations. Key highlights include results from the Phase 1/1b study of the BCL2 inhibitor sonrotoclax in combination with obinutuzumab for treatment-naïve CLL/SLL, as well as initial data on a triplet regimen of sonrotoclax, BRUKINSA (zanubrutinib), and obinutuzumab. Preliminary findings from a Phase 1/1b study of BGB-21447, a next-generation BCL2 inhibitor in patients with B-cell non-Hodgkin lymphoma, will also be shared. These results will be presented at the ASH 2025 meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeOne Medicines AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20251120303213) on November 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BeOne Medicines Unveils Promising Clinical Data on Novel BCL2 and BTK Therapies at ASH 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeOne Medicines Unveils Promising Clinical Data on Novel BCL2 and BTK Therapies at ASH 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-20 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BeOne Medicines Unveils Promising Clinical Data on Novel BCL2 and BTK Therapies at ASH 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BeOne Medicines AG has announced the presentation of new clinical data from its hematology portfolio at the upcoming 67th American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> Annual Meeting and Exposition, scheduled for December 6-9, 2025, in Orlando, Florida. Nearly 50 abstracts have been accepted, including six oral presentations. Key highlights include results from the Phase 1/1b study of the BCL2 inhibitor sonrotoclax in combination with obinutuzumab for treatment-naïve CLL/SLL, as well as initial data on a triplet regimen of sonrotoclax, BRUKINSA (zanubrutinib), and obinutuzumab. Preliminary findings from a Phase 1/1b study of BGB-21447, a next-generation BCL2 inhibitor in patients with B-cell non-Hodgkin lymphoma, will also be shared. These results will be presented at the ASH 2025 meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeOne Medicines AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20251120303213) on November 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL9nrpyV:1","article_id":"2584380781","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584380781","pubTimestamp":1763636451,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BeOne Medicines AG has announced the presentation of new clinical data from its hematology portfolio at the upcoming 67th American Society of Hematology  Annual Meeting and Exposition, scheduled for December 6-9, 2025, in Orlando, Florida. Nearly 50 abstracts have been accepted, including six oral presentations. Key highlights include results from the Phase 1/1b study of the BCL2 inhibitor sonrotoclax in combination with obinutuzumab for treatment-nave CLL/SLL, as well as initial data on a triplet regimen of sonrotoclax, BRUKINSA , and obinutuzumab. Preliminary findings from a Phase 1/1b study of BGB-21447, a next-generation BCL2 inhibitor in patients with B-cell non-Hodgkin lymphoma, will also be shared. These results will be presented at the ASH 2025 meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688235":"百济神州","BK0239":"医药制造"},"translate_title":"BeOne Medicines在ASH 2025上公布了有关新型BCL2和BTK疗法的有希望的临床数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688235":0.9},"content_text":"BeOne Medicines Unveils Promising Clinical Data on Novel BCL2 and BTK Therapies at ASH 2025\n    \n\n        BeOne Medicines AG has announced the presentation of new clinical data from its hematology portfolio at the upcoming 67th American Society of Hematology $(ASH)$ Annual Meeting and Exposition, scheduled for December 6-9, 2025, in Orlando, Florida. Nearly 50 abstracts have been accepted, including six oral presentations. Key highlights include results from the Phase 1/1b study of the BCL2 inhibitor sonrotoclax in combination with obinutuzumab for treatment-naïve CLL/SLL, as well as initial data on a triplet regimen of sonrotoclax, BRUKINSA (zanubrutinib), and obinutuzumab. Preliminary findings from a Phase 1/1b study of BGB-21447, a next-generation BCL2 inhibitor in patients with B-cell non-Hodgkin lymphoma, will also be shared. These results will be presented at the ASH 2025 meeting.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeOne Medicines AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20251120303213) on November 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584380781","isCrawlerRequest":true}